Surface engineering for lymphocyte programming

Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green

doi:10.1016/j.addr.2017.05.005

Surface engineering for lymphocyte programming

Adv Drug Deliv Rev. 2017 May 15:114:102-115. doi: 10.1016/j.addr.2017.05.005. Epub 2017 May 10.

Authors

Elana Ben-Akiva¹, Randall A Meyer², David R Wilson², Jordan J Green³

Affiliations

¹ Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Nanobiotechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
² Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Nanobiotechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
³ Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Institute for Nanobiotechnology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Johns Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Materials Science and Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Chemical and Biomolecular Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA. Electronic address: green@jhu.edu.

Abstract

The once nascent field of immunoengineering has recently blossomed to include approaches to deliver and present biomolecules to program diverse populations of lymphocytes to fight disease. Building upon improved understanding of the molecular and physical mechanics of lymphocyte activation, varied strategies for engineering surfaces to activate and deactivate T-Cells, B-Cells and natural killer cells are in preclinical and clinical development. Surfaces have been engineered at the molecular level in terms of the presence of specific biological factors, their arrangement on a surface, and their diffusivity to elicit specific lymphocyte fates. In addition, the physical and mechanical characteristics of the surface including shape, anisotropy, and rigidity of particles for lymphocyte activation have been fine-tuned. Utilizing these strategies, acellular systems have been engineered for the expansion of T-Cells and natural killer cells to clinically relevant levels for cancer therapies as well as engineered to program B-Cells to better combat infectious diseases.

Keywords: Artificial antigen presenting cell; Lymphocyte engineering; Microparticle; Nanoparticle.

Publication types

Review

MeSH terms

Animals
Antigen Presentation*
Antigens, Surface / immunology
Antigens, Surface / metabolism
B-Lymphocytes / cytology
B-Lymphocytes / immunology
Cell Engineering*
Humans
Killer Cells, Natural / cytology
Killer Cells, Natural / immunology
Lymphocyte Activation*
Lymphocytes / cytology
Lymphocytes / immunology*
Lymphocytes / metabolism*
T-Lymphocytes / cytology
T-Lymphocytes / immunology

Substances

Antigens, Surface

Abstract

Publication types

MeSH terms

Substances

Grants and funding